# DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

> **NCT03255083** · PHASE1 · TERMINATED · sponsor: **Daiichi Sankyo** · enrollment: 13 (actual)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** DS-1205c
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT03255083
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-10
- **Primary completion:** 2020-09-04
- **Final completion:** 2020-09-04
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** This study was terminated based on a business decision by the Sponsor.
- **Last updated:** 2022-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03255083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03255083, "DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03255083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*